Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
PHASE2CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
May 31, 2015
Primary Completion Date
November 30, 2015
Study Completion Date
January 31, 2016
Conditions
Treatment of Hepatitis C
Interventions
DRUG
Ledipasvir/Sofosbuvir FDC
Trial Locations (1)
90036
Peter J. Ruane, MD, Inc., Los Angeles
All Listed Sponsors
lead
Peter J. Ruane, M.D., Inc.
OTHER
NCT02480387 - Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection | Biotech Hunter | Biotech Hunter